Loading biomarkers…
Loading biomarkers…
Biomarkers
A biomarker entry is an identity record — what is measured, by which assay family, the NCIt concept it maps to and the gene it is anchored to. Every link to cancers, drugs, approvals and trials is derived at query time from curated evidence and registries; nothing on this page grades clinical utility or states a threshold of its own.
| Biomarker | Kind | Gene(s) | NCIt | Cancers | Drugs | Approvals | Tissue-agnostic | Active trials |
|---|---|---|---|---|---|---|---|---|
| BCMA (TNFRSF17)BCMA · B-cell maturation antigen · TNFRSF17 · CD269 | Cell-surface target | TNFRSF17 | C128845 | 0 | 0 | 3 | — | 0 |
| CD19CD19-positive · CD19 antigen · B-lymphocyte antigen CD19 | Cell-surface target | CD19 | C129255 | 0 | 0 | 4 | — | 0 |
| CD20 (MS4A1)CD20 · CD20-positive · MS4A1 · B-lymphocyte antigen CD20 | Cell-surface target | MS4A1 |
| 1 |
| 1 |
| 4 |
| — |
| 1 |
| CD30 (TNFRSF8)CD30 · CD30-positive · TNFRSF8 · Ki-1 antigen | Cell-surface target | TNFRSF8 | C129257 | 0 | 0 | 1 | — | 0 |
| CD33CD33-positive · Siglec-3 · myeloid cell surface antigen CD33 | Cell-surface target | CD33 | C132228 | 0 | 0 | 5 | — | 0 |
| CD38CD38-positive · ADP-ribosyl cyclase 1 | Cell-surface target | CD38 | C147087 | 0 | 0 | 14 | — | 0 |
| PSMA (FOLH1) expressionPSMA · FOLH1 · prostate-specific membrane antigen · PSMA-positive | Cell-surface target | FOLH1 | C153464 | 0 | 0 | 1 | — | 0 |
| Somatostatin receptor (SSTR) expressionSSTR · SSTR2 · somatostatin receptor-positive · SSTR imaging | Cell-surface target | SSTR2 | C128873 | 0 | 0 | 1 | — | 0 |
| Circulating tumor DNA (ctDNA)ctDNA · liquid biopsy · cell-free tumor DNA · plasma genotyping | Circulating tumor DNA | none | C113243 | — | — | 1 | — | — |
| ALK rearrangement / fusionALK-positive · ALK rearrangement · EML4-ALK · ALK fusion | Gene alteration | ALK | C142135 | 20 | 16 | 178 | Tumor-agnostic · 3 | 226 |
| BCR-ABL1 fusion (Philadelphia chromosome)BCR-ABL1 · BCR::ABL1 · Philadelphia chromosome · Ph+ | Gene alteration | ABL1, BCR1 variant anchor | C94600 | 6 | 8 | 209 | — | 39 |
| BRAF mutation (any)BRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF | Gene alteration | BRAF | C40430 | 32 | 43 | 458 | Tumor-agnostic · 4 | 628 |
| BRAF V600Ep.V600E · BRAF V600E-mutant · c.1799T>A | Gene alteration | BRAF1 variant anchor | C98342 | 24 | 29 | 364 | Tumor-agnostic · 4 | 472 |
| BRCA1 mutationBRCA1-mutated · gBRCA1 · germline BRCA1 · somatic BRCA1 | Gene alteration | BRCA1 | C19635 | 16 | 15 | 179 | — | 499 |
| BRCA2 mutationBRCA2-mutated · gBRCA2 · germline BRCA2 · somatic BRCA2 | Gene alteration | BRCA2 | C19636 | 15 | 15 | 223 | — | 554 |
| CDKN2A deletion / lossCDKN2A loss · p16 loss · CDKN2A homozygous deletion · 9p21 deletion | Gene alteration | CDKN2A2 variant anchors | C41615 | 11 | 5 | 91 | — | 17 |
| EGFR exon 19 deletionex19del · EGFR del19 · exon 19 del | Gene alteration | EGFR1 variant anchor | C126892 | 2 | 13 | 225 | — | 332 |
| EGFR exon 20 insertionex20ins · EGFR exon 20 ins | Gene alteration | EGFR1 variant anchor | C125605 | 2 | 7 | 74 | — | 148 |
| EGFR L858Rp.L858R · exon 21 L858R · c.2573T>G | Gene alteration | EGFR1 variant anchor | C98515 | 5 | 17 | 274 | — | 430 |
| EGFR mutation (any sensitizing or resistance mutation)EGFR-mutant · EGFR-mutated · EGFR activating mutation | Gene alteration | EGFR | C98357 | 20 | 39 | 475 | — | 934 |
| EGFR T790Mp.T790M · gatekeeper mutation · c.2369C>T | Gene alteration | EGFR1 variant anchor | C98503 | 5 | 13 | 190 | — | 270 |
| ESR1 mutationESR1-mutated · ESR1 ligand-binding domain mutation · D538G · Y537S | Gene alteration | ESR13 variant anchors | C136629 | 1 | 6 | 162 | — | 170 |
| FGFR2 fusion / rearrangementFGFR2 rearrangement · FGFR2-BICC1 · FGFR2 fusion-positive | Gene alteration | FGFR22 variant anchors | C150616 | 5 | 4 | 19 | — | 6 |
| FGFR3 alteration (mutation or fusion)FGFR3 mutation · FGFR3 fusion · FGFR3-TACC3 · S249C | Gene alteration | FGFR3 | C150618 | 9 | 12 | 94 | — | 84 |
| FLT3 mutation (ITD / TKD)FLT3-ITD · FLT3-TKD · FLT3 internal tandem duplication · FLT3-mutated | Gene alteration | FLT3 | C128919 | 8 | 24 | 133 | — | 148 |
| HER2 (ERBB2) activating mutationHER2 mutation · ERBB2 mutation · HER2 exon 20 insertion · HER2-mutant NSCLC | Gene alteration | ERBB22 variant anchors | C96866 | 4 | 7 | 100 | Tumor-agnostic · 1 | 102 |
| IDH1 mutationIDH1-mutated · IDH1 R132 · R132H · R132C | Gene alteration | IDH1 | C118389 | 13 | 11 | 260 | — | 332 |
| IDH2 mutationIDH2-mutated · R140Q · R172K | Gene alteration | IDH2 | C118390 | 8 | 3 | 26 | — | 174 |
| JAK2 V617Fp.V617F · JAK2-positive · c.1849G>T | Gene alteration | JAK21 variant anchor | C105908 | 4 | 2 | 20 | — | 2 |
| KIT mutationc-KIT mutation · KIT exon 11 · KIT D816V · CD117 | Gene alteration | KIT | C39712 | 15 | 14 | 253 | — | 63 |
| KRAS G12Cp.G12C · KRAS G12C-mutated · c.34G>T | Gene alteration | KRAS1 variant anchor | C98365 | 6 | 15 | 168 | — | 279 |
| KRAS mutation (any)KRAS-mutant · KRAS-mutated · RAS mutation | Gene alteration | KRAS | C41361 | 26 | 57 | 910 | Tumor-agnostic · 4 | 1,650 |
| MET amplificationMET amp · c-MET amplification · MET copy-number gain | Gene alteration | MET1 variant anchor | C43532 | 7 | 8 | 84 | — | 103 |
| MET exon 14 skippingMETex14 · MET exon 14 alteration · METΔ14 | Gene alteration | MET2 variant anchors | C131179 | 3 | 3 | 26 | — | 24 |
| NPM1 mutationNPM1-mutated · NPMc+ · NPM1 exon 12 mutation | Gene alteration | NPM12 variant anchors | C82429 | 2 | 6 | 24 | — | 32 |
| NRAS mutationNRAS-mutant · NRAS-mutated | Gene alteration | NRAS | C41381 | 13 | 20 | 333 | Tumor-agnostic · 4 | 349 |
| NTRK gene fusionNTRK fusion-positive · TRK fusion · ETV6-NTRK3 · NTRK1/2/3 fusion | Gene alteration | NTRK1, NTRK2, NTRK3 | C183255 | 32 | 10 | 146 | Tumor-agnostic · 8 | 93 |
| PDGFRA mutationPDGFRA D842V · PDGFRA exon 18 · PDGFRA-mutant | Gene alteration | PDGFRA1 variant anchor | C39718 | 2 | 4 | 133 | — | 18 |
| PIK3CA mutationPIK3CA-mutated · PIK3CA-altered · H1047R · E545K | Gene alteration | PIK3CA3 variant anchors | C96271 | 18 | 50 | 550 | Tumor-agnostic · 2 | 1,074 |
| RET fusionRET rearrangement · RET fusion-positive · KIF5B-RET · CCDC6-RET | Gene alteration | RET | C131069 | 10 | 12 | 164 | Tumor-agnostic · 3 | 78 |
| ROS1 rearrangement / fusionROS1-positive · ROS1 rearrangement · CD74-ROS1 | Gene alteration | ROS1 | C131071 | 11 | 10 | 63 | Tumor-agnostic · 4 | 64 |
| TP53 mutationTP53-mutated · p53 mutation · TP53-mutant | Gene alteration | TP53 | C118396 | 26 | 24 | 444 | — | 1,109 |
| Androgen receptor (AR)AR · AR-positive · androgen receptor expression | Hormone receptor | AR | C94297 | 3 | 8 | 98 | — | 92 |
| Estrogen receptor (ER)ER · ER-positive · ESR1 expression · estrogen receptor alpha | Hormone receptor | ESR1 | C15492 | 1 | 7 | 186 | — | 177 |
| Progesterone receptor (PR)PR · PgR · PR-positive · PGR expression | Hormone receptor | PGR | C15496 | 1 | 2 | 42 | — | 33 |
| Homologous recombination deficiency (HRD)HRD · HRD-positive · genomic instability score · HRR deficiency | HR deficiency | none | C120465 | — | — | 3 | — | — |
| PD-L1 expressionPD-L1 · CD274 · B7-H1 · programmed death-ligand 1 | Immune marker | CD2742 variant anchors | C128554 | 10 | 7 | 379 | Tumor-agnostic · 1 | 651 |
| Microsatellite instability-high (MSI-H)MSI-H · MSI-high · microsatellite instability · MSI | MSI / MMR | MLH1, MSH2, MSH6, PMS2 | C36493 | 4 | 4 | 160 | Tumor-agnostic · 1 | 50 |
| Mismatch repair deficiency (dMMR)dMMR · MMR-deficient · MMR deficiency · loss of MMR protein expression | MSI / MMR | MLH1, MSH2, MSH6, PMS2 | C136712 | 4 | 4 | 160 | Tumor-agnostic · 2 | 50 |
| AR-V7 splice variantAR-V7 · androgen receptor variant 7 · AR splice variant 7 | Other | AR1 variant anchor | C135616 | 1 | 2 | 43 | — | 54 |
| HER2 (ERBB2) overexpression / amplificationHER2 · HER2/neu · ERBB2 · HER2-positive | Protein expression | ERBB23 variant anchors | C68748 | 22 | 27 | 526 | Tumor-agnostic · 2 | 957 |
| Ki-67 labeling indexKi-67 · Ki67 · MKI67 · proliferation index | Protein expression | MKI67 | C157250 | 2 | 0 | 0 | — | 0 |
| 17p deletion (del(17p))del(17p) · del17p · 17p13 deletion · TP53 deletion | Signature | TP532 variant anchors | C36499 | 1 | 1 | 82 | — | 68 |
| Tumor mutational burden-high (TMB-H)TMB-H · TMB-high · tumor mutation burden · TMB | Tumor mutational burden | none | C156025 | — | — | 1 | Tumor-agnostic · 1 | — |
Data updated 19 days agoSource updated NCIt 26.08ecodes verified 2026-09-11
Counts are computed over ingested sources only (CIViC, ClinicalTrials.gov, openFDA, Health Canada, PubMed) and say nothing about biomarkers or links that are not yet ingested. A trial counted here tests a linked drug in a linked cancer; it does not necessarily select patients on the biomarker.